Discover
ALLO
Allogene Therapeutics, Inc.
2.05
8 x 2.01
7 x 2.07
bid
ask
+
0.07
3.54%
300 @ 04:00 PM
2.02 -0.03 (1.46%)
| Ytd | 49.64% | |
| 1y | 91.59% |
1.92
day range
2.08
1.05
52 week range
3.06
| Open | 1.94 | Prev Close | 1.98 | Low | 1.92 | High | 2.08 | Mkt Cap | 707.57M |
| Vol | 4.60M | Avg Vol | 7.99M | EPS | -0.77 | P/E | -2.66 | Forward P/E | -1.50 |
| Beta | 0.84 | Short Ratio | 11.46 | Inst. Own | 80.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.95 | 200-d Avg | 1.90 | 1yr Est | 9.04 |
| Income Statement | |||
| Total Revenue | 4.64M | ||
| Revenues (USD) | 4.64M | ||
| Gross Profit | 4.64M | ||
| Operating Expenses | 51.56M | ||
| Research and Development Expense | 30.72M | ||
| Selling, General and Administrative Expense | 20.84M | ||
| Operating Income | -46.92M | ||
| Interest Expense | 343.00K | ||
| Net Income | -42.68M | ||
| Net Income Common Stock | -42.68M | ||
| Net Income Common Stock (USD) | -42.68M | ||
| Consolidated Income | -42.68M | ||
| Earnings per Basic Share | -0.13 | ||
| Earnings per Basic Share (USD) | -0.13 | ||
| Earnings per Diluted Share | -0.13 | ||
| Earning Before Interest & Taxes (EBIT) | -42.33M | ||
| Earning Before Interest & Taxes (USD) | -42.33M | ||
| Weighted Average Shares | 328.93M | ||
| Weighted Average Shares Diluted | 328.93M | ||
| Balance Sheet | |||
| Cash and Equivalents | 48.92M | ||
| Cash and Equivalents (USD) | 48.92M | ||
| Investments | 384.96M | ||
| Investments Current | 293.98M | ||
| Investments Non-Current | 90.99M | ||
| Current Assets | 340.00M | ||
| Property, Plant & Equipment Net | 105.12M | ||
| Total Assets | 550.09M | ||
| Current Liabilities | 31.73M | ||
| Total Liabilities | 113.92M | ||
| Accumulated Retained Earnings (Deficit) | -2.10B | ||
| Accumulated Other Comprehensive Income | -518.00K | ||
| Shareholders Equity | 436.18M | ||
| Shareholders Equity (USD) | 436.18M | ||
| Assets Non-Current | 210.09M | ||
| Liabilities Non-Current | 82.19M | ||
| Trade and Non-Trade Payables | 5.96M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.65M | ||
| Net Cash Flow from Financing | 187.87M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.32M | ||
| Capital Expenditure | -150.00K | ||
| Issuance (Purchase) of Equity Shares | 187.87M | ||
| Net Cash Flow from Investing | -147.56M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -147.41M | ||
| Net Cash Flow from Operations | -32.00M | ||
| Share Based Compensation | 12.44M | ||